Hunter Smith - Nov 14, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Financial Officer
Signature
/s/ Hunter Smith
Stock symbol
RYTM
Transactions as of
Nov 14, 2023
Transactions value $
-$282,013
Form type
4
Date filed
11/16/2023, 04:05 PM
Previous filing
Jun 30, 2023
Next filing
Nov 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $82.6K +12K +19.54% $6.88 73.4K Nov 14, 2023 Direct
transaction RYTM Common Stock Sale -$365K -12K -16.35% $30.38 61.4K Nov 14, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -12K -7.45% $0.00 149K Nov 14, 2023 Common Stock 12K $6.88 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock options is fully vested.